If You’ve Tried Other Treatments Without Success, You May Already Qualify
A large number of people researching ketamine therapy are not sure whether they qualify, and a surprising number who would qualify have been told or assumed they do not. The clinical criteria for ketamine candidacy are more specific than some people expect and more accessible than others fear. At The Mood Center, serving patients at our Columbia and Annapolis locations in Maryland, we evaluate each patient individually, and our free consultation exists precisely so that people can get a real answer rather than guessing based on incomplete information.
The Foundation: What Ketamine Therapy Is Designed to Treat
IV ketamine at our clinic is not a first-line treatment, but it is evaluated more flexibly than many patients expect. Candidacy is based on the full clinical picture: symptom severity, prior treatments attempted, urgency factors like severe suicidal ideation, and how well standard options have worked or been tolerated. There is no rigid minimum number of failed antidepressant trials required to be considered. A patient who has tried one medication and found it intolerable, or whose symptoms are severe enough that waiting through additional trials is not clinically appropriate, may still qualify. We evaluate each person’s history individually and honestly.
The clinical concept of treatment-resistant depression (TRD) is defined in research as major depressive disorder that has not responded adequately to at least two antidepressant medications at therapeutic doses, maintained for a sufficient duration. That benchmark is useful context, and patients who meet it are clearly appropriate candidates. But IV ketamine’s off-label use allows for clinical flexibility that the research definition does not fully capture, and we apply that flexibility in the interest of getting the right patients access to care rather than creating unnecessary barriers.
Beyond depression, we offer IV ketamine for a range of conditions, including anxiety disorders, PTSD, OCD, bipolar disorder, chronic and neuropathic pain, migraines, suicidal ideation, and addiction. Candidacy criteria vary by condition. For mental health conditions, the common thread is that standard approaches have not produced sufficient relief. For pain conditions, a history of conventional pain management that has not worked is the relevant starting point. We evaluate each patient’s history in full before making any treatment recommendation.
IM Ketamine: A Second Administration Route Available at Our Clinic
In addition to IV ketamine, The Mood Center offers intramuscular (IM) ketamine, a route of administration that is less commonly discussed but clinically well-established and appropriate for a meaningful subset of patients.
The core difference between IV and IM ketamine is how the medication enters the body. IV administration delivers ketamine directly into the bloodstream via an intravenous line, enabling precise, real-time dosing adjustments throughout the infusion. IM administration involves an injection into muscle tissue, from which the medication is absorbed into the bloodstream over a slightly longer window. Both routes deliver ketamine systemically and produce the same antidepressant mechanism of action. The clinical experience is similar, though the timing of absorption and the ability to fine-tune dosing mid-session differ between the two.
IM ketamine is often a practical option for patients who have needle-access challenges, a history of difficult IV placement, or who simply find the prospect of an IV line more uncomfortable than a single injection. It is not a lesser option clinically the evidence base for IM ketamine’s antidepressant effects is well-supported, and the candidacy criteria we apply are the same as those for IV: symptom severity, prior treatment history, urgency, and overall medical picture.
The conditions we treat with IM ketamine overlap substantially with those for which we offer IV ketamine, including treatment-resistant depression, anxiety disorders, PTSD, OCD, and suicidal ideation. Like IV ketamine, IM treatment is self-pay. Call our office for current session pricing and package options, as rates may differ from IV.
If you are uncertain which administration route is right for you, that is exactly the kind of question our free consultation is designed to address. Our medical team will review your history and preferences and help you understand which option IV, IM, or SPRAVATO® is the most appropriate fit for your situation.
IM Ketamine: A Second Administration Route Available at Our Clinic
In addition to IV ketamine, The Mood Center offers intramuscular (IM) ketamine, a route of administration that is less commonly discussed but clinically well-established and appropriate for a meaningful subset of patients.
The core difference between IV and IM ketamine is how the medication enters the body. IV administration delivers ketamine directly into the bloodstream via an intravenous line, enabling precise, real-time dosing adjustments throughout the infusion. IM administration involves an injection into muscle tissue, from which the medication is absorbed into the bloodstream over a slightly longer window. Both routes deliver ketamine systemically and produce the same antidepressant mechanism of action. The clinical experience is similar, though the timing of absorption and the ability to fine-tune dosing mid-session differ between the two.
IM ketamine is often a practical option for patients who have needle-access challenges, a history of difficult IV placement, or who simply find the prospect of an IV line more uncomfortable than a single injection. Clinically, it is not a lesser option. The evidence base for IM ketamine’s antidepressant effects is well-supported, and the candidacy criteria we apply are the same as those for IV: symptom severity, prior treatment history, urgency, and overall medical picture.
The conditions we treat with IM ketamine overlap substantially with those for which we offer IV ketamine, including treatment-resistant depression, anxiety disorders, PTSD, OCD, and suicidal ideation. Like IV ketamine, IM treatment is self-pay. Call our office for current session pricing and package options, as rates may differ from IV.
If you are uncertain which administration route is right for you, that is exactly the kind of question our free consultation is designed to address. Our medical team will review your history and preferences and help you understand which option, whether IV, IM, or SPRAVATO®, is the most appropriate fit for your situation.
SPRAVATO® as an FDA-Approved Option for Specific Diagnoses
For patients whose diagnosis includes treatment-resistant depression or major depressive disorder with suicidal thoughts or actions, SPRAVATO® (esketamine) is a separate option worth understanding, and one with a meaningfully different regulatory and insurance profile than IV ketamine.
SPRAVATO® is FDA-approved specifically for TRD and MDD with suicidal ideation, and unlike IV ketamine, it carries a strict FDA threshold: candidacy requires documented inadequate response to at least two oral antidepressants. Insurance prior authorization typically reflects this requirement. It is worth noting that SPRAVATO® was recently approved for use as a monotherapy, meaning patients no longer need to be currently taking a concurrent oral antidepressant alongside it, which removes a barrier that previously applied. It is self-administered by the patient under direct clinical supervision at our facility and cannot be taken home.
SPRAVATO® is covered by most major insurance plans for patients who meet the FDA criteria. We are in-network with CareFirst, Anthem, Aetna, Cigna, United Healthcare, Tricare, Maryland Medicaid, and Medicare. Co-pays vary by plan, and our team handles prior authorization and verifies benefits before treatment begins.
Understanding the distinction between IV ketamine and SPRAVATO® is part of the candidacy conversation we have with every patient whose diagnosis potentially qualifies them for either. They share a mechanism but differ in regulatory status, administration method, candidacy requirements, and cost. IV ketamine is self-pay; SPRAVATO® is insurance-covered for qualifying patients. Discussing both options with our team and with your prescribing provider gives you the most complete picture of what is available and appropriate for your situation.
The Key Clinical Markers We Evaluate
Several factors shape how we approach a candidacy evaluation. The first is treatment history: specifically, what you have tried, at what doses, for how long, and how you responded. This history tells us whether you genuinely meet criteria for treatment resistance or whether there are untried options within the standard of care that might be worth pursuing first. We are honest about this distinction. If someone comes to us who has been on a single low-dose SSRI for three weeks and stopped because of initial side effects, the clinical conversation looks different from someone who has completed four adequate antidepressant trials over several years.
The second factor is the current diagnosis and symptom profile. Major depressive disorder and treatment-resistant depression are the primary indications for which ketamine’s evidence base is most robust. Anxiety disorders, PTSD, and OCD are conditions for which we also offer ketamine-based treatments, and the candidacy evaluation for these involves reviewing the same categories of information (symptom severity, prior treatment response, functional impact) in the context of what the research supports for each condition specifically.
Medical history and current medications are also part of the evaluation. Ketamine therapy is not appropriate for patients with uncontrolled high blood pressure or certain cardiac or pulmonary conditions without medical clearance from the relevant specialist. It is not recommended for patients with a history of psychosis or schizophrenia. Patients with those conditions in their history are not automatically excluded from all our services, but they are not appropriate candidates for ketamine specifically, and we discuss alternative options during the evaluation. Current medications are reviewed in detail, as certain combinations require specific clinical attention.
Finally, minimum age matters: we accept patients 18 and older.
What Disqualifies Someone from Ketamine Therapy
Being honest about contraindications is as important as explaining who qualifies. Ketamine therapy is not appropriate for everyone, and we do not approach the evaluation as an exercise in confirming that every patient should proceed. Active psychosis is a contraindication. Uncontrolled cardiovascular conditions require medical clearance before treatment can be considered. A history of substance misuse is not an automatic disqualifier, but it is a factor that requires careful clinical discussion. Ketamine has a known potential for misuse at high doses, and we screen for this as part of every evaluation.
Pregnancy and certain medication combinations also require individualized assessment. The evaluation process is the appropriate venue for working through these questions with our medical team, which is why we encourage anyone who is uncertain about their candidacy to have the conversation rather than self-select out based on incomplete information.
Addressing the Cost and Fear Barriers to Finding Out
Many people who may qualify for ketamine therapy never find out because the cost concern stops them before the evaluation. The consultation is free. You do not need to commit to treatment to find out whether you qualify or what your options are. IV ketamine is self-pay and not currently covered by insurance: $425 per session, or $395 per session when purchasing a package of 6, which is our standard initial course. SPRAVATO® is covered by most major insurance plans for patients who meet criteria. Co-pays vary by plan, and our team verifies benefits and handles prior authorization. Patient financing is available for IV ketamine patients who need it.
Fear of the ketamine experience is the other reason people delay. The dissociation associated with the infusion (the altered perception, the floating quality) is real, and for some patients, it is the single thing that has kept them from taking a step they otherwise believe makes sense. Research from the National Institutes of Health confirms that side effects from antidepressant-dose IV ketamine are mild and brief. The experience is supervised, contained, and supported by our clinical team from start to finish. The orientation we provide before your first session ensures that nothing about the process is a surprise.
Frequently Asked Questions About Ketamine Therapy in Columbia, MD
Do I need a referral to be evaluated for ketamine therapy?
No. All patients are welcome to self-refer. We strongly recommend that patients remain under the care of a medical or psychiatric provider throughout treatment, and we will work closely with your existing providers to coordinate care. However, a referral is not required to schedule a consultation or begin the evaluation process.
What if I’ve only tried one antidepressant? Do I still qualify?
Potentially, yes, and this is one of the most important things to understand about IV ketamine candidacy. Unlike SPRAVATO®, which carries a strict FDA threshold requiring inadequate response to at least two oral antidepressants, IV ketamine is an off-label treatment evaluated based on the full clinical picture. Symptom severity, urgency, how well prior treatments worked or were tolerated, and overall history all factor in. If you have significant symptoms and standard options have not been effective or suitable for you, the evaluation will give you a clear answer about whether treatment is appropriate, rather than applying a fixed trial count as a gate.
Is ketamine therapy right for chronic pain conditions?
We offer IV ketamine for chronic and neuropathic pain as well as migraines, and candidacy for pain indications involves reviewing your pain history, prior treatments, and overall medical picture. Pain disorder sessions may involve longer infusion times than psychiatric indications, and pricing varies accordingly. Call us for details specific to pain treatment. Results vary by individual.
Can I pursue ketamine therapy while continuing to work with my psychiatrist?
Yes, and we encourage it. We recommend that patients continue working with their existing psychiatric or medical providers for medication management and ongoing care. We will communicate with your providers as appropriate to ensure coordinated treatment. If you do not currently have a psychiatrist, we can provide a referral.
Key Takeaways
- IV ketamine candidacy is evaluated based on the full clinical picture: symptom severity, prior treatment response, urgency, and medical history, rather than a fixed minimum number of failed antidepressant trials. Patients who have not completed two adequate trials may still qualify if standard options have not worked or are not suitable.
- SPRAVATO® (esketamine) carries a stricter FDA threshold (inadequate response to at least two oral antidepressants) but is now approved as a monotherapy, meaning patients no longer need to be on a concurrent oral antidepressant. It is covered by most major insurance plans for eligible patients.
- Ketamine-based treatment at our clinic is also available for anxiety, PTSD, OCD, bipolar disorder, chronic pain, migraines, suicidal ideation, and addiction, with candidacy evaluated individually for each condition based on treatment history, symptom severity, and medical background.
- Absolute contraindications include active psychosis and uncontrolled cardiovascular conditions. Other factors, such as medication history and substance use, are evaluated on a case-by-case basis rather than automatically disqualifying.
- Results vary by individual, and the free consultation exists specifically so patients can get a clear, honest answer about their candidacy rather than making assumptions based on incomplete information.
Ready to Find Out if You Qualify? Schedule a Free Consultation at Our Columbia or Annapolis Location
If you are looking for ketamine therapy Columbia, MD area and wondering whether this treatment option is right for you, the next step is a straightforward one. The Mood Center offers free consultations at both our Columbia and Annapolis locations, with evening and Saturday appointments available to fit your schedule. You do not need a referral or commit to anything before speaking with our team. We will review your history and provide an honest assessment of the options that may be appropriate for your situation. Call 443-940-MOOD or schedule online today.
References
- PubMed. Antidepressant efficacy in treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/23982301/
- National Institutes of Health. Ketamine side effects. https://www.nih.gov/news-events/news-releases/side-effects-mild-brief-single-antidepressant-dose-intravenous-ketamine
- National Institute of Mental Health. New hope for rapid-acting depression treatment (2024). https://www.nimh.nih.gov/news/science-updates/2024/new-hope-for-rapid-acting-depression-treatment
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy and SPRAVATO® (esketamine) should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. Nothing in this article constitutes a diagnosis or a guarantee of candidacy or treatment outcomes. Consult a qualified provider to evaluate whether ketamine therapy is appropriate for your specific situation. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.
